Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)
The role of spleen size and splenectomy for the prediction of post‐allogeneic hematopoietic stem cell transplant (allo‐HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort of 1195 myelofibrosis patients transplanted between 2000‐2017 after either fludarabine‐b...
Saved in:
| Published in | American journal of hematology Vol. 96; no. 1; pp. 69 - 79 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken, USA
John Wiley & Sons, Inc
01.01.2021
Wiley Subscription Services, Inc Wiley |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0361-8609 1096-8652 1096-8652 |
| DOI | 10.1002/ajh.26020 |
Cover
| Abstract | The role of spleen size and splenectomy for the prediction of post‐allogeneic hematopoietic stem cell transplant (allo‐HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort of 1195 myelofibrosis patients transplanted between 2000‐2017 after either fludarabine‐busulfan or fludarabine‐melphalan regimens. Overall, splenectomy was performed in 202 (16.9%) patients and its use decreased over time (28.3% in 2000‐2009 vs 14.1% in 2010‐2017 period). By multivariate analysis, splenectomy was associated with less NRM (HR 0.64, 95% CI 0.44‐0.93, P = .018) but increased risk of relapse (HR 1.43, 95% CI 1.01‐2.02, P = .042), with no significant impact on OS (HR 0.86, 95% CI 0.67‐1.12, P = .274). However, in subset analysis comparing the impact of splenectomy vs specific spleen sizes, for patients with progressive disease, an improved survival was seen in splenectomised subjects compared to those patients with a palpable spleen length ≥ 15 cm (HR 0.44, 95% CI 0.28‐0.69, P < .001), caused by a significant reduction in NRM (HR 0.26, 95% CI 0.14‐0.49, P < .001), without significantly increased relapse risk (HR 1.47, 95% CI 0.87‐2.49, P = .147). Overall, despite the possible biases typical of retrospective cohorts, this study highlights the potential detrimental effect of massive splenomegaly in transplant outcome and supports the role of splenectomy for myelofibrosis patients with progressive disease and large splenomegaly. |
|---|---|
| AbstractList | The role of spleen size and splenectomy for the prediction of post‐allogeneic hematopoietic stem cell transplant (allo‐HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort of 1195 myelofibrosis patients transplanted between 2000‐2017 after either fludarabine‐busulfan or fludarabine‐melphalan regimens. Overall, splenectomy was performed in 202 (16.9%) patients and its use decreased over time (28.3% in 2000‐2009 vs 14.1% in 2010‐2017 period). By multivariate analysis, splenectomy was associated with less NRM (HR 0.64, 95% CI 0.44‐0.93, P = .018) but increased risk of relapse (HR 1.43, 95% CI 1.01‐2.02, P = .042), with no significant impact on OS (HR 0.86, 95% CI 0.67‐1.12, P = .274). However, in subset analysis comparing the impact of splenectomy vs specific spleen sizes, for patients with progressive disease, an improved survival was seen in splenectomised subjects compared to those patients with a palpable spleen length ≥ 15 cm (HR 0.44, 95% CI 0.28‐0.69, P < .001), caused by a significant reduction in NRM (HR 0.26, 95% CI 0.14‐0.49, P < .001), without significantly increased relapse risk (HR 1.47, 95% CI 0.87‐2.49, P = .147). Overall, despite the possible biases typical of retrospective cohorts, this study highlights the potential detrimental effect of massive splenomegaly in transplant outcome and supports the role of splenectomy for myelofibrosis patients with progressive disease and large splenomegaly. The role of spleen size and splenectomy for the prediction of post-allogeneic hematopoietic stem cell transplant (allo-HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort of 1195 myelofibrosis patients transplanted between 2000-2017 after either fludarabine-busulfan or fludarabine-melphalan regimens. Overall, splenectomy was performed in 202 (16.9%) patients and its use decreased over time (28.3% in 2000-2009 vs 14.1% in 2010-2017 period). By multivariate analysis, splenectomy was associated with less NRM (HR 0.64, 95% CI 0.44-0.93, P = .018) but increased risk of relapse (HR 1.43, 95% CI 1.01-2.02, P = .042), with no significant impact on OS (HR 0.86, 95% CI 0.67-1.12, P = .274). However, in subset analysis comparing the impact of splenectomy vs specific spleen sizes, for patients with progressive disease, an improved survival was seen in splenectomised subjects compared to those patients with a palpable spleen length ≥ 15 cm (HR 0.44, 95% CI 0.28-0.69, P < .001), caused by a significant reduction in NRM (HR 0.26, 95% CI 0.14-0.49, P < .001), without significantly increased relapse risk (HR 1.47, 95% CI 0.87-2.49, P = .147). Overall, despite the possible biases typical of retrospective cohorts, this study highlights the potential detrimental effect of massive splenomegaly in transplant outcome and supports the role of splenectomy for myelofibrosis patients with progressive disease and large splenomegaly.The role of spleen size and splenectomy for the prediction of post-allogeneic hematopoietic stem cell transplant (allo-HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort of 1195 myelofibrosis patients transplanted between 2000-2017 after either fludarabine-busulfan or fludarabine-melphalan regimens. Overall, splenectomy was performed in 202 (16.9%) patients and its use decreased over time (28.3% in 2000-2009 vs 14.1% in 2010-2017 period). By multivariate analysis, splenectomy was associated with less NRM (HR 0.64, 95% CI 0.44-0.93, P = .018) but increased risk of relapse (HR 1.43, 95% CI 1.01-2.02, P = .042), with no significant impact on OS (HR 0.86, 95% CI 0.67-1.12, P = .274). However, in subset analysis comparing the impact of splenectomy vs specific spleen sizes, for patients with progressive disease, an improved survival was seen in splenectomised subjects compared to those patients with a palpable spleen length ≥ 15 cm (HR 0.44, 95% CI 0.28-0.69, P < .001), caused by a significant reduction in NRM (HR 0.26, 95% CI 0.14-0.49, P < .001), without significantly increased relapse risk (HR 1.47, 95% CI 0.87-2.49, P = .147). Overall, despite the possible biases typical of retrospective cohorts, this study highlights the potential detrimental effect of massive splenomegaly in transplant outcome and supports the role of splenectomy for myelofibrosis patients with progressive disease and large splenomegaly. The role of spleen size and splenectomy for the prediction of post‐allogeneic hematopoietic stem cell transplant (allo‐HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort of 1195 myelofibrosis patients transplanted between 2000‐2017 after either fludarabine‐busulfan or fludarabine‐melphalan regimens. Overall, splenectomy was performed in 202 (16.9%) patients and its use decreased over time (28.3% in 2000‐2009 vs 14.1% in 2010‐2017 period). By multivariate analysis, splenectomy was associated with less NRM (HR 0.64, 95% CI 0.44‐0.93, P = .018) but increased risk of relapse (HR 1.43, 95% CI 1.01‐2.02, P = .042), with no significant impact on OS (HR 0.86, 95% CI 0.67‐1.12, P = .274). However, in subset analysis comparing the impact of splenectomy vs specific spleen sizes, for patients with progressive disease, an improved survival was seen in splenectomised subjects compared to those patients with a palpable spleen length ≥ 15 cm (HR 0.44, 95% CI 0.28‐0.69, P < .001), caused by a significant reduction in NRM (HR 0.26, 95% CI 0.14‐0.49, P < .001), without significantly increased relapse risk (HR 1.47, 95% CI 0.87‐2.49, P = .147). Overall, despite the possible biases typical of retrospective cohorts, this study highlights the potential detrimental effect of massive splenomegaly in transplant outcome and supports the role of splenectomy for myelofibrosis patients with progressive disease and large splenomegaly. |
| Author | Polverelli, Nicola Robin, Marie Castagna, Luca Sirait, Tiarlan Beauvais, David Helbig, Grzegorz Vrhovac, Radovan Hayden, Patrick Maertens, Johan Mear, Jean‐Baptiste Hernández‐Boluda, Juan Carlos Karakasis, Dimitrios Kröger, Nicolaus Chevallier, Patrice Russo, Domenico Passweg, Jakob Angelucci, Emanuele Bornhäuser, Martin Reményi, Péter Mauff, Katya Czerw, Tomasz Finke, Jürgen Rubio, Marie Thérèse Mohty, Mohamad Wreede, Liesbeth Beelen, Dietrich Rifòn, Jose Yakoub‐Agha, Ibrahim McLornan, Donal |
| Author_xml | – sequence: 1 givenname: Nicola orcidid: 0000-0001-6297-9697 surname: Polverelli fullname: Polverelli, Nicola email: nicola.polverelli@unibs.it organization: University of Brescia – sequence: 2 givenname: Katya surname: Mauff fullname: Mauff, Katya organization: LUMC – sequence: 3 givenname: Nicolaus surname: Kröger fullname: Kröger, Nicolaus organization: University Hospital Eppendorf – sequence: 4 givenname: Marie orcidid: 0000-0003-1388-9876 surname: Robin fullname: Robin, Marie organization: Hôpital Saint‐Louis, APHP – sequence: 5 givenname: Dietrich surname: Beelen fullname: Beelen, Dietrich organization: University Hospital of Essen – sequence: 6 givenname: David surname: Beauvais fullname: Beauvais, David organization: CHU Lille – sequence: 7 givenname: Patrice surname: Chevallier fullname: Chevallier, Patrice organization: CHU Nantes – sequence: 8 givenname: Mohamad surname: Mohty fullname: Mohty, Mohamad organization: INSERM – sequence: 9 givenname: Jakob surname: Passweg fullname: Passweg, Jakob organization: University Hospital Basel – sequence: 10 givenname: Marie Thérèse surname: Rubio fullname: Rubio, Marie Thérèse organization: CHRU BRABOIS – sequence: 11 givenname: Johan surname: Maertens fullname: Maertens, Johan organization: University Hospital Gasthuisberg – sequence: 12 givenname: Jürgen surname: Finke fullname: Finke, Jürgen organization: University of Freiburg – sequence: 13 givenname: Martin surname: Bornhäuser fullname: Bornhäuser, Martin organization: University Hospital Dresded – sequence: 14 givenname: Radovan surname: Vrhovac fullname: Vrhovac, Radovan organization: University Hospital Center Rebro – sequence: 15 givenname: Grzegorz surname: Helbig fullname: Helbig, Grzegorz organization: Silesian Medical Academy – sequence: 16 givenname: Jean‐Baptiste surname: Mear fullname: Mear, Jean‐Baptiste organization: Centre Hospitalier Universitaire de Rennes – sequence: 17 givenname: Luca surname: Castagna fullname: Castagna, Luca organization: Centre de Recherche en Cancérologie de Marseille – sequence: 18 givenname: Péter surname: Reményi fullname: Reményi, Péter organization: Dél‐pesti Centrumkórház – sequence: 19 givenname: Emanuele orcidid: 0000-0002-6512-6080 surname: Angelucci fullname: Angelucci, Emanuele organization: IRCCS Ospedale Policlinico San Martino – sequence: 20 givenname: Dimitrios surname: Karakasis fullname: Karakasis, Dimitrios organization: Evangelismos Hospital – sequence: 21 givenname: Jose surname: Rifòn fullname: Rifòn, Jose organization: Clínica Universitaria de Navarra – sequence: 22 givenname: Tiarlan surname: Sirait fullname: Sirait, Tiarlan organization: LUMC – sequence: 23 givenname: Domenico surname: Russo fullname: Russo, Domenico organization: University of Brescia – sequence: 24 givenname: Liesbeth surname: Wreede fullname: Wreede, Liesbeth organization: LUMC – sequence: 25 givenname: Tomasz orcidid: 0000-0003-3108-4035 surname: Czerw fullname: Czerw, Tomasz organization: Maria Sklodowska‐Curie National Research Institute of Oncology – sequence: 26 givenname: Juan Carlos orcidid: 0000-0002-4289-3113 surname: Hernández‐Boluda fullname: Hernández‐Boluda, Juan Carlos organization: Hospital Clínico Universitario de Valencia – sequence: 27 givenname: Patrick surname: Hayden fullname: Hayden, Patrick organization: St. James's Hospital – sequence: 28 givenname: Donal surname: McLornan fullname: McLornan, Donal organization: Guy's and St Thomas' NHS Foundation Trust and University College London Hospitals – sequence: 29 givenname: Ibrahim surname: Yakoub‐Agha fullname: Yakoub‐Agha, Ibrahim email: ibrahim.yakoubagha@chru-lille.fr organization: Université de Lille |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33064301$$D View this record in MEDLINE/PubMed https://amu.hal.science/hal-03623698$$DView record in HAL |
| BookMark | eNp9klFv0zAQx8M0xLrBA18AWeJlQ-rm2Eka81amQoeKeBnPkeNcWhfHzhxnVfj0XNoxpCH2FNv3u7v_3T-n0bF1FqLobUwvY0rZldxuLllGGT2KJjEV2TTPUnYcTSjPYjxTcRKddt2W0jhOcvoqOuGcZgmn8eTF0U3TShWIq0nXGgBLOv0LiLTV_m5BBdcMxFni-qBcA92ISmPcGoNakQ00MrjWaQh4U2AMCV5aTJY2yKAxs3aeNAMYV-vSu053H8mceAh4brG-vh_7STNghJQDCRsgauOdxXqNNHptpVUaG--c_6ntmrTSh72kEjbS1KOgRe9dCxLVO0QxOvYsjXPVfpRGeu92_wg7X3z6dnvxOnpZS9PBm4fvWfTj8-L2ejldff9ycz1fTVXCGJ2yWUVZKgCyWFCVi0rk2SzjpUh5TpM8rdMZ4wJDStY8rRPOSsgqqGdlySBhnJ9FHw51e9vKYYc7LFqvUdpQxLQYjSzQyGJvJMIXBxgnfMSc1MVyvirGN_SW8Uzk9zGy5we29e6uhy4Uje5GJ6QF13cFS9I4T0Wc54i-f4JuXe9x-SM1wzFEIjKk3j1QfdlA9dj_z2_zV51CDzsP9bOTXD1hlT7sH-3Q5rmMnTYw_L90Mf-6PGT8Btel9KM |
| CitedBy_id | crossref_primary_10_1016_j_leukres_2024_107530 crossref_primary_10_1080_14656566_2023_2192350 crossref_primary_10_1002_ajh_27252 crossref_primary_10_1002_ajh_27570 crossref_primary_10_1016_S2352_3026_23_00305_8 crossref_primary_10_1007_s11899_024_00742_x crossref_primary_10_1111_bjh_19186 crossref_primary_10_1038_s41375_021_01294_2 crossref_primary_10_1016_j_bulcan_2022_09_003 crossref_primary_10_1016_j_clml_2024_06_012 crossref_primary_10_1080_10428194_2023_2167493 crossref_primary_10_1016_j_jtct_2021_11_006 crossref_primary_10_1038_s41409_022_01649_y crossref_primary_10_3389_fonc_2023_1205387 crossref_primary_10_1002_ajh_26714 crossref_primary_10_1002_jha2_734 crossref_primary_10_1182_bloodadvances_2023009886 crossref_primary_10_1016_j_jtct_2022_02_004 crossref_primary_10_1016_j_retram_2023_103400 crossref_primary_10_1007_s00277_025_06270_9 crossref_primary_10_3389_fonc_2024_1396435 crossref_primary_10_1016_j_clml_2025_02_003 crossref_primary_10_1186_s12964_024_01877_3 crossref_primary_10_1002_ajh_27292 crossref_primary_10_1038_s41409_024_02437_6 crossref_primary_10_1182_hematology_2021000279 crossref_primary_10_1002_ajh_27274 crossref_primary_10_1080_10428194_2024_2422835 crossref_primary_10_1002_ajh_27559 crossref_primary_10_1016_j_retram_2024_103476 crossref_primary_10_1097_TXD_0000000000001451 crossref_primary_10_1002_ajh_26349 crossref_primary_10_1182_hematology_2023000453 crossref_primary_10_1016_j_clml_2024_01_008 crossref_primary_10_1182_blood_2023021218 crossref_primary_10_1016_j_clml_2024_09_001 crossref_primary_10_1038_s41375_021_01276_4 crossref_primary_10_1038_s41409_024_02220_7 crossref_primary_10_1080_17474086_2024_2409438 crossref_primary_10_1002_ajh_26054 crossref_primary_10_1002_ajh_27660 crossref_primary_10_1002_ajh_27262 crossref_primary_10_1038_s41409_021_01540_2 crossref_primary_10_1002_ajh_26050 crossref_primary_10_1002_ajh_26857 crossref_primary_10_1002_ajh_26654 crossref_primary_10_3390_cells11030553 crossref_primary_10_1158_0008_5472_CAN_21_2930 crossref_primary_10_1007_s00277_023_05353_9 crossref_primary_10_1016_j_jtct_2025_03_006 crossref_primary_10_3389_frhem_2023_1328503 crossref_primary_10_1038_s41409_023_01968_8 crossref_primary_10_1016_S2352_3026_22_00330_1 |
| Cites_doi | 10.1182/blood-2018-12-890889 10.1016/j.bbmt.2017.03.034 10.1111/bjh.16537 10.1038/s41409-020-0934-1 10.1038/modpathol.2012.33 10.1002/cncr.32664 10.1016/j.bbmt.2006.11.004 10.1016/j.bbmt.2017.03.002 10.1182/blood-2005-05-2004 10.1089/scd.2011.0068 10.1182/blood-2009-09-245837 10.1620/tjem.228.295 10.1016/j.bbmt.2018.12.064 10.1038/s41375-020-0815-z 10.3324/haematol.2019.227603 10.1016/j.bbmt.2014.03.017 10.3324/haematol.2018.206151 10.1177/2040620712459746 10.3324/haematol.12828 10.1016/j.bbmt.2006.05.015 10.1007/s11899-010-0044-z 10.1038/leu.2015.233 10.1182/blood-2012-02-414631 10.1056/NEJMoa1110556 10.1182/blood.V97.7.2180 10.1182/blood-2009-07-234880 10.1056/NEJMoa1110557 10.18632/oncotarget.18674 10.1038/s41409-019-0718-7 10.1182/blood-2011-08-372904 10.1016/j.bbmt.2015.10.005 10.1016/j.bbmt.2016.02.019 10.1002/cncr.22021 10.1016/j.clml.2014.12.008 10.1038/leu.2017.169 10.1182/blood.V97.11.3665 10.1182/blood-2008-07-170449 10.1182/blood-2018-02-785923 10.3324/haematol.2018.193763 10.1038/bmt.2009.188 10.1046/j.1365-2141.1998.00998.x 10.1002/ajh.25053 10.1182/blood-2013-03-488098 10.1002/ajh.26034 10.1182/blood-2014-04-572545 10.3389/fonc.2019.01186 10.1016/j.bbmt.2009.10.025 10.1002/ajh.24572 10.4061/2011/954275 10.1182/blood.V95.7.2226 10.1111/bjh.15407 10.1182/blood-2016-03-643544 10.3324/haematol.2014.119545 |
| ContentType | Journal Article |
| Copyright | 2020 Wiley Periodicals LLC 2020 Wiley Periodicals LLC. 2021 Wiley Periodicals LLC. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2020 Wiley Periodicals LLC – notice: 2020 Wiley Periodicals LLC. – notice: 2021 Wiley Periodicals LLC. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 1XC ADTOC UNPAY |
| DOI | 10.1002/ajh.26020 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Hyper Article en Ligne (HAL) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1096-8652 |
| EndPage | 79 |
| ExternalDocumentID | 10.1002/ajh.26020 oai_HAL_hal_03623698v1 33064301 10_1002_ajh_26020 AJH26020 |
| Genre | article Clinical Trial Multicenter Study Journal Article |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 23M 24P 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDPE ABEML ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EGARE EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IH2 IX1 J0M J5H JPC KBYEO KD1 KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6P MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ TEORI TR2 UB1 V2E V8K VH1 W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 1XC ADTOC UNPAY |
| ID | FETCH-LOGICAL-c4220-27d0259ee6190c89d986763b95380485f5723990ccaf35f432be6def7bb2e4233 |
| IEDL.DBID | DR2 |
| ISSN | 0361-8609 1096-8652 |
| IngestDate | Tue Aug 19 19:46:30 EDT 2025 Tue Sep 09 06:31:31 EDT 2025 Wed Oct 01 14:45:35 EDT 2025 Fri Jul 25 09:09:51 EDT 2025 Wed Feb 19 02:30:04 EST 2025 Wed Oct 01 03:09:33 EDT 2025 Thu Apr 24 23:09:04 EDT 2025 Wed Jan 22 16:32:57 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2020 Wiley Periodicals LLC. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4220-27d0259ee6190c89d986763b95380485f5723990ccaf35f432be6def7bb2e4233 |
| Notes | Nicola Polverelli and Katya Mauff have contributed equally. Donal McLornan and Ibrahim Yakoub‐Agha have senior joint authorship. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-6512-6080 0000-0003-3108-4035 0000-0003-1388-9876 0000-0002-4289-3113 0000-0001-6297-9697 0000-0001-8536-7781 0000-0002-7264-808X 0000-0003-1224-091X 0000-0003-3142-5581 0000-0003-2171-657X 0000-0003-4524-8782 0000-0003-3732-5442 0000-0001-5103-9966 0000-0003-4257-5980 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.26020 |
| PMID | 33064301 |
| PQID | 2470489496 |
| PQPubID | 866345 |
| PageCount | 11 |
| ParticipantIDs | unpaywall_primary_10_1002_ajh_26020 hal_primary_oai_HAL_hal_03623698v1 proquest_miscellaneous_2451859188 proquest_journals_2470489496 pubmed_primary_33064301 crossref_primary_10_1002_ajh_26020 crossref_citationtrail_10_1002_ajh_26020 wiley_primary_10_1002_ajh_26020_AJH26020 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2021 2021-01-00 20210101 2021-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: January 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: New York |
| PublicationTitle | American journal of hematology |
| PublicationTitleAlternate | Am J Hematol |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc – name: Wiley |
| References | 2017; 8 2012; 120 2010; 16 2012; 366 2015; 100 2020; 126 2000; 95 2013; 122 2009; 113 2020; 55 2009; 114 2014; 20 2017; 31 2018; 132 2020; 96 2010; 115 2019; 25 2005; 106 1998; 91 1999; 93 2012; 25 2010; 5 2012; 21 2001; 97 2014; 124 2015; 15 2019; 9 2018; 182 2006; 12 2017; 23 2018; 103 2019; 104 2020; 105 2016; 127 2008; 93 2007; 13 2012; 228 2010; 45 2011; 2011 2020; 190 2012; 3 2015; 29 2017; 92 2020 1998; 103 2018; 93 2006; 107 2019; 133 2012; 119 2016; 22 e_1_2_7_5_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_17_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_49_1 e_1_2_7_28_1 Barosi G (e_1_2_7_51_1) 1998; 91 e_1_2_7_50_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_52_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_54_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_56_1 e_1_2_7_37_1 e_1_2_7_39_1 e_1_2_7_4_1 e_1_2_7_8_1 e_1_2_7_18_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_48_1 e_1_2_7_27_1 e_1_2_7_29_1 Guardiola P (e_1_2_7_6_1) 1999; 93 e_1_2_7_30_1 e_1_2_7_53_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_55_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_38_1 33219701 - Am J Hematol. 2021 Jan;96(1):12-13 |
| References_xml | – volume: 29 start-page: 2126 issue: 11 year: 2015 end-page: 2133 article-title: Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group publication-title: Leukemia. – volume: 45 start-page: 458 issue: 3 year: 2010 end-page: 463 article-title: Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type publication-title: Bone Marrow Transplant – volume: 115 start-page: 1703 issue: 9 year: 2010 end-page: 1708 article-title: A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG‐MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) publication-title: Blood. – volume: 126 start-page: 1243 issue: 6 year: 2020 end-page: 1252 article-title: Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis publication-title: Cancer. – volume: 22 start-page: 432 issue: 3 year: 2016 end-page: 440 article-title: Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors publication-title: Biol Blood Marrow Transplant – volume: 95 start-page: 2226 issue: 7 year: 2000 end-page: 2233 article-title: Splenectomy in myelofibrosis with myeloid metaplasia: a single‐institution experience with 223 patients publication-title: Blood. – volume: 16 start-page: 358 issue: 3 year: 2010 end-page: 367 article-title: Outcome of transplantation for myelofibrosis publication-title: Biol Blood Marrow Transplant – volume: 228 start-page: 295 issue: 4 year: 2012 end-page: 299 article-title: Splenic irradiation as a component of a reduced‐intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly publication-title: Tohoku J Exp Med – volume: 9 start-page: 1186 year: 2019 article-title: Mechanisms Underlying the Anti‐inflammatory and Immunosuppressive Activity of Ruxolitinib publication-title: Front Oncol. – volume: 103 start-page: 505 issue: 2 year: 1998 end-page: 511 article-title: Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia publication-title: Br J Haematol. – volume: 127 start-page: 2391 issue: 20 year: 2016 end-page: 2405 article-title: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia publication-title: Blood. – volume: 25 start-page: 815 issue: 6 year: 2012 end-page: 827 article-title: Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome‐negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition publication-title: Mod Pathol – volume: 122 start-page: 1395 issue: 8 year: 2013 end-page: 1398 article-title: Revised response criteria for myelofibrosis: International Working Group‐Myeloproliferative Neoplasms Research and Treatment (IWG‐MRT) and European LeukemiaNet (ELN) consensus report publication-title: Blood. – volume: 103 start-page: e446 issue: 10 year: 2018 end-page: e449 article-title: Genomic characterization of spleens in patients with myelofibrosis publication-title: Haematologica. – volume: 97 start-page: 3665 issue: 11 year: 2001 end-page: 3667 article-title: Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia publication-title: Blood. – volume: 106 start-page: 2912 issue: 8 year: 2005 end-page: 2919 article-title: Hematopoietic cell transplantation (HCT)‐specific comorbidity index: a new tool for risk assessment before allogeneic HCT publication-title: Blood. – volume: 120 start-page: 1202 issue: 6 year: 2012 end-page: 1209 article-title: Long‐term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls publication-title: Blood. – volume: 119 start-page: 2657 issue: 11 year: 2012 end-page: 2664 article-title: The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation publication-title: Blood. – volume: 12 start-page: 954 issue: 9 year: 2006 end-page: 964 article-title: Performance status and comorbidity predict transplant‐related mortality after allogeneic hematopoietic cell transplantation publication-title: Biol Blood Marrow Transplant – volume: 97 start-page: 2180 issue: 7 year: 2001 end-page: 2181 article-title: Splenectomy and hemopoietic stem cell transplantation for myelofibrosis publication-title: Blood. – volume: 113 start-page: 2895 issue: 13 year: 2009 end-page: 2901 article-title: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment publication-title: Blood. – volume: 23 start-page: 958 issue: 6 year: 2017 end-page: 964 article-title: The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation publication-title: Biol Blood Marrow Transplant – volume: 2011 year: 2011 article-title: Spleen as a site for hematopoiesis of a distinct antigen presenting cell type publication-title: Stem Cells Int. – volume: 190 start-page: 437 year: 2020 end-page: 441 article-title: Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT publication-title: Br J Haematol – volume: 107 start-page: 361 issue: 2 year: 2006 end-page: 370 article-title: Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic publication-title: Cancer. – volume: 182 start-page: 418 issue: 3 year: 2018 end-page: 422 article-title: Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT publication-title: Br J Haematol. – volume: 104 start-page: 659 issue: 4 year: 2019 end-page: 668 article-title: State‐of‐the‐art review: allogeneic stem cell transplantation for myelofibrosis in 2019 publication-title: Haematologica. – volume: 20 start-page: 1274 issue: 9 year: 2014 end-page: 1281 article-title: Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis publication-title: Biol Blood Marrow Transplant – volume: 15 start-page: 214 issue: 4 year: 2015 end-page: 221. e211 article-title: Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT‐I publication-title: Clin Lymphoma Myeloma Leuk – volume: 100 start-page: 1139 issue: 9 year: 2015 end-page: 1145 article-title: A pooled analysis of overall survival in COMFORT‐I and COMFORT‐II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis publication-title: Haematologica. – volume: 92 start-page: 37 issue: 1 year: 2017 end-page: 41 article-title: Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients publication-title: Am J Hematol. – volume: 31 start-page: 2726 year: 2017 end-page: 2731 article-title: A clinical‐molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis publication-title: Leukemia. – volume: 22 start-page: 1206 issue: 7 year: 2016 end-page: 1211 article-title: Outcome after transplantation according to reduced‐intensity conditioning regimen in patients undergoing transplantation for myelofibrosis publication-title: Biol Blood Marrow Transplant – volume: 124 start-page: 1183 issue: 7 year: 2014 end-page: 1191 article-title: MPD‐RC 101 prospective study of reduced‐intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis publication-title: Blood. – volume: 96 start-page: 80 issue: 1 year: 2020 end-page: 88 article-title: Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: a French nationwide study publication-title: Am J Hematol. – volume: 55 start-page: 681 issue: 4 year: 2020 end-page: 694 article-title: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) publication-title: Bone Marrow Transplant. – volume: 93 start-page: 1514 issue: 10 year: 2008 end-page: 1522 article-title: Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20‐year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) publication-title: Haematologica. – volume: 93 start-page: 2831 issue: 9 year: 1999 end-page: 2838 article-title: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study publication-title: Blood. – volume: 132 start-page: 492 issue: 5 year: 2018 end-page: 500 article-title: How I treat myelofibrosis after failure of JAK inhibitors publication-title: Blood. – volume: 114 start-page: 5264 issue: 26 year: 2009 end-page: 5270 article-title: Allogeneic stem cell transplantation after reduced‐intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation publication-title: Blood. – volume: 25 start-page: 932 issue: 5 year: 2019 end-page: 940 article-title: Busulfan‐ or thiotepa‐based conditioning in myelofibrosis: a phase ii multicenter randomized study from the GITMO Group publication-title: Biol Blood Marrow Transplant – volume: 93 start-page: 649 issue: 5 year: 2018 end-page: 654 article-title: Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis publication-title: Am J Hematol. – volume: 13 start-page: 355 issue: 3 year: 2007 end-page: 365 article-title: Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia publication-title: Biol Blood Marrow Transplant – volume: 21 start-page: 702 issue: 5 year: 2012 end-page: 709 article-title: Splenectomy influences homing of transplanted stem cells in bone marrow‐ablated mice publication-title: Stem Cells and Development. – volume: 23 start-page: 1095 issue: 7 year: 2017 end-page: 1101 article-title: Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation publication-title: Biol Blood Marrow Transplant – volume: 366 start-page: 787 issue: 9 year: 2012 end-page: 798 article-title: JAK inhibition with ruxolitinib vs best available therapy for myelofibrosis publication-title: N Engl J Med – volume: 55 start-page: 2224 year: 2020 end-page: 2233 article-title: Multidimensional geriatric assessment for elderly hematological patients (≥60years) submitted to allogeneic stem cell transplantation. A French‐Italian 10‐year experience on 228 patients publication-title: Bone Marrow Transplant. – volume: 366 start-page: 799 issue: 9 year: 2012 end-page: 807 article-title: A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis publication-title: N Engl J Med. – volume: 8 start-page: 79073 year: 2017 end-page: 79086 article-title: Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis publication-title: Oncotarget – volume: 3 start-page: 341 issue: 6 year: 2012 end-page: 354 article-title: Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians publication-title: Ther Adv Hematol. – year: 2020 article-title: Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation publication-title: Leukemia. – volume: 105 start-page: 1138 issue: 4 year: 2020 end-page: 1146 article-title: Allogeneic peripheral blood stem cell transplantation with anti‐thymocyte globulin vs allogeneic bone marrow transplantation without anti‐thymocyte globulin publication-title: Haematologica. – volume: 133 start-page: 2233 issue: 20 year: 2019 end-page: 2242 article-title: Comprehensive clinical‐molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation publication-title: Blood. – volume: 91 start-page: 3630 issue: 10 year: 1998 end-page: 3636 article-title: Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia publication-title: Blood. – volume: 5 start-page: 53 issue: 2 year: 2010 end-page: 61 article-title: Reduced‐intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis publication-title: Curr Hematol Malig Rep – ident: e_1_2_7_34_1 doi: 10.1182/blood-2018-12-890889 – volume: 91 start-page: 3630 issue: 10 year: 1998 ident: e_1_2_7_51_1 article-title: Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia publication-title: Blood. – ident: e_1_2_7_54_1 doi: 10.1016/j.bbmt.2017.03.034 – ident: e_1_2_7_20_1 doi: 10.1111/bjh.16537 – ident: e_1_2_7_33_1 doi: 10.1038/s41409-020-0934-1 – ident: e_1_2_7_50_1 doi: 10.1038/modpathol.2012.33 – ident: e_1_2_7_45_1 doi: 10.1002/cncr.32664 – ident: e_1_2_7_35_1 doi: 10.1016/j.bbmt.2006.11.004 – ident: e_1_2_7_8_1 doi: 10.1016/j.bbmt.2017.03.002 – ident: e_1_2_7_31_1 doi: 10.1182/blood-2005-05-2004 – ident: e_1_2_7_53_1 doi: 10.1089/scd.2011.0068 – ident: e_1_2_7_26_1 doi: 10.1182/blood-2009-09-245837 – ident: e_1_2_7_47_1 doi: 10.1620/tjem.228.295 – ident: e_1_2_7_11_1 doi: 10.1016/j.bbmt.2018.12.064 – ident: e_1_2_7_24_1 doi: 10.1038/s41375-020-0815-z – ident: e_1_2_7_23_1 doi: 10.3324/haematol.2019.227603 – ident: e_1_2_7_40_1 doi: 10.1016/j.bbmt.2014.03.017 – ident: e_1_2_7_16_1 doi: 10.3324/haematol.2018.206151 – ident: e_1_2_7_13_1 doi: 10.1177/2040620712459746 – ident: e_1_2_7_36_1 doi: 10.3324/haematol.12828 – ident: e_1_2_7_32_1 doi: 10.1016/j.bbmt.2006.05.015 – ident: e_1_2_7_38_1 doi: 10.1007/s11899-010-0044-z – ident: e_1_2_7_3_1 doi: 10.1038/leu.2015.233 – ident: e_1_2_7_42_1 doi: 10.1182/blood-2012-02-414631 – ident: e_1_2_7_29_1 doi: 10.1056/NEJMoa1110556 – volume: 93 start-page: 2831 issue: 9 year: 1999 ident: e_1_2_7_6_1 article-title: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study publication-title: Blood. – ident: e_1_2_7_7_1 doi: 10.1182/blood.V97.7.2180 – ident: e_1_2_7_10_1 doi: 10.1182/blood-2009-07-234880 – ident: e_1_2_7_12_1 doi: 10.1056/NEJMoa1110557 – ident: e_1_2_7_15_1 doi: 10.18632/oncotarget.18674 – ident: e_1_2_7_56_1 doi: 10.1038/s41409-019-0718-7 – ident: e_1_2_7_41_1 doi: 10.1182/blood-2011-08-372904 – ident: e_1_2_7_17_1 doi: 10.1016/j.bbmt.2015.10.005 – ident: e_1_2_7_22_1 doi: 10.1016/j.bbmt.2016.02.019 – ident: e_1_2_7_28_1 doi: 10.1002/cncr.22021 – ident: e_1_2_7_44_1 doi: 10.1016/j.clml.2014.12.008 – ident: e_1_2_7_27_1 doi: 10.1038/leu.2017.169 – ident: e_1_2_7_49_1 doi: 10.1182/blood.V97.11.3665 – ident: e_1_2_7_2_1 doi: 10.1182/blood-2008-07-170449 – ident: e_1_2_7_30_1 doi: 10.1182/blood-2018-02-785923 – ident: e_1_2_7_48_1 doi: 10.3324/haematol.2018.193763 – ident: e_1_2_7_9_1 doi: 10.1038/bmt.2009.188 – ident: e_1_2_7_46_1 doi: 10.1046/j.1365-2141.1998.00998.x – ident: e_1_2_7_5_1 doi: 10.1002/ajh.25053 – ident: e_1_2_7_55_1 doi: 10.1182/blood-2013-03-488098 – ident: e_1_2_7_19_1 doi: 10.1002/ajh.26034 – ident: e_1_2_7_39_1 doi: 10.1182/blood-2014-04-572545 – ident: e_1_2_7_14_1 doi: 10.3389/fonc.2019.01186 – ident: e_1_2_7_37_1 doi: 10.1016/j.bbmt.2009.10.025 – ident: e_1_2_7_4_1 doi: 10.1002/ajh.24572 – ident: e_1_2_7_52_1 doi: 10.4061/2011/954275 – ident: e_1_2_7_18_1 doi: 10.1182/blood.V95.7.2226 – ident: e_1_2_7_25_1 doi: 10.1111/bjh.15407 – ident: e_1_2_7_21_1 doi: 10.1182/blood-2016-03-643544 – ident: e_1_2_7_43_1 doi: 10.3324/haematol.2014.119545 – reference: 33219701 - Am J Hematol. 2021 Jan;96(1):12-13 |
| SSID | ssj0011480 |
| Score | 2.519457 |
| Snippet | The role of spleen size and splenectomy for the prediction of post‐allogeneic hematopoietic stem cell transplant (allo‐HCT) outcome in myelofibrosis remains... The role of spleen size and splenectomy for the prediction of post-allogeneic hematopoietic stem cell transplant (allo-HCT) outcome in myelofibrosis remains... |
| SourceID | unpaywall hal proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 69 |
| SubjectTerms | Allografts Antineoplastic Combined Chemotherapy Protocols - administration & dosage Busulfan Busulfan - administration & dosage Cancer Disease-Free Survival Female Fludarabine Follow-Up Studies Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Immunology Life Sciences Male Melphalan Melphalan - administration & dosage Middle Aged Multivariate analysis Myelofibrosis Organ Size Primary Myelofibrosis - mortality Primary Myelofibrosis - pathology Primary Myelofibrosis - therapy Registries Retrospective Studies Spleen Spleen - pathology Spleen - surgery Splenectomy Splenomegaly Stem cell transplantation Survival Rate Transplantation Transplants & implants Vidarabine - administration & dosage Vidarabine - analogs & derivatives |
| SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5KKoE48Gh5GBU0PITCwSF-29wMahUqUnFopHJy_dilAce2Ypsq_fXM7NoWpYCQuNnxbnbWO7Mz45n5lrGXfhInlkgt3UVtqtvcN_QYNaEe256XuDy2rZiqkedH7mxhH544J905p1QLo_Ahhg9uJBlyvyYBrzKh9vkuum--ib-eTdAgN9Fn36bBzBHbXhx9Cj-rCKWh-65M8jDQUMdrx-yxhX7ue0kjXT-jfMirxuYtdrMtqnhzHuf5ZTtWKqKDO-y0n4LKP_k2aZtkkl78gu74H3O8y253RiqEiqvusS1e7LDdsEAHfbWBVyDTRuX3-B12Y95F53evbX2QJZdQCqgrStGAennBIS4yeV9QgAD7lwWUbYOk8JqaUuQfuZgvU5AAsmVVLqmyEiimAI0EX89jVSFVANrYsNrwHGUiwde5rN9CCGverMu-ZhTHUzgrkGwAzVtIFf4vrNDl-KJOI67hXAUJoELRkSQRXkEuiKA-QAG1ymiVY8oEfzmVlYStvELYeP_d_Pj1fbY42D9-P9O7Myb01DbRcza9DK2-gHN0JKepH2SB7-KWmwSoCHBzc4TjUfXvFBldWI6wLTPhbsaFlyQmR1PUesBGRVnwRwzcdOoI7IM8btgZN_0sk-fnZMISwrCExsY9n0VpB8BO54DkkYKONiNc6kgutcaeD00rhTry20b4YobnhBM-Cz9G9BuZJZYb-N8Nje31vBx1u1MdmbaHdAZ24Grs2fAY9xVa2LjgZUttHIOwDX1fYw-VDAxDWeS2ombQ2ItBKP5G51jy-J9bROHhTF48_qc_3GOjZt3yJ2gNNsnTTuJ_AC_LYtE priority: 102 providerName: Unpaywall |
| Title | Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT) |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fajh.26020 https://www.ncbi.nlm.nih.gov/pubmed/33064301 https://www.proquest.com/docview/2470489496 https://www.proquest.com/docview/2451859188 https://amu.hal.science/hal-03623698 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.26020 |
| UnpaywallVersion | publishedVersion |
| Volume | 96 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1096-8652 dateEnd: 20241002 omitProxy: true ssIdentifier: ssj0011480 issn: 0361-8609 databaseCode: DIK dateStart: 19980101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0361-8609 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1096-8652 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011480 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwEDdlSDw-8Nh4BMZkHkLlQ7q8H_ApoE1lohNCqzQkpMhObFZIk6pJmLq_nju7CRoDhPjWNGflEt-d73x3PxPyPOKMuzJzzQBWU9MTkW0yWAlN5oUhDwTzXIbdyJPDYDz1Do794wF53fXCaHyIfsMNNUPZa1Rwxuvdn6Ch7OvJCJxxB-N12_VVivZjDx2Fbr6l85S2GQVW3KEKWc5uP_LcWnT5BCshL7qZN8i1tlyw1SkrivMerFqC9m-Rzx3zuvLk26ht-Cg7-wXX8T_f7ja5uXZNaaJl6Q4ZiHKTbCUlhOXzFX1BVbGo2oXfJFcn65z81qXBO9VoSStJ6wUWZtB6diYoK3N1XWJaAMZXJa3aBtgQNZJivh9kV8wyqmBjq0U1w35KipkE2ijI9YLpvqiSgmdN5ytRgCZw-JSz-hVN6FI0y6rrFIXnaXQVylcUnFqaadRfOodA44s-g7impzo1QBegMIolRCkoJDLUpSVoretY1TNVWb96lbkCq7zA2HDvzeTo5V0y3d87ejs21ydLmJnnQLzshDn4erEQED5aWRTncRSAoeUxmH8wab70Q-z5tUC8petLz3W4CHIhQ84dAQ6oe49slFUpHhAaZJYvYQxItu3lwonyXJ2ak0tXStuVBhl2MpZma9h1PP2jSDVgtJPCVKdqqg3ytCddaKyR3xLBh-nvIzr4OHmf4n_ojLhBHH23DbLdyXG6tkl16ngh8Bl7cWCQJ_1tsCY4sawUVYs0vo2IhlFkkPta_vtHuRiswnpgkGe9QvyNz6GS7z9TpMnBWP14-O-kj8h1B4uK1B7YNtlolq14DF5hw3eU-u-QK9PDD8mnH0k1Yfk |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF5CkSg8cPQAQ4HhEAoPTn0fiJcArdKS9KFKpb4gy8cuDTh2FDtU6a9nZjc2KgWEeIvjWXnsnZmd2Zn5lrFXQRIntkht3cPVVHd4YOoxroR67Ph-4vHYsWPqRh4deYMT5_DUPe2wd00vjMKHaDfcSDOkvSYFpw3p3Z-oofHXsx564xYG7DcoP0dq-fG4BY8iR99QmUpTDzwjbHCFDGu3HXppNbp-RrWQVx3N22x9Uczi5Xmc55d9WLkI7d9lnxv2Ve3Jt96iTnrpxS_Ijv_7fvfYnZV3Cn0lTvdZhxcbbLNfYGQ-XcJrkPWiciN-g90crdLym9c6B7LXEkoB1YxqM6CaXHCIi0xeF5QZwPFlAeWiRj54RaSU8kfx5ZMUJHJsOSsn1FIJlEyAWqKu57FqjSoAnWuYLnmOypDgt5xUb6EPc17Py6ZZFJ-nAFYgWQL6tZAq4F-YYqzxRR1DXMG5yg7ADHVGskRABbkghprMBFSqlFU-U1b2y1eZSrzKK4x1996Pxm-22Mn-3vjDQF8dLqGnjoUhs-Vn6O6FnGMEaaRBmIWBh7Y2CXEFQKvmCtentl8DJVzYrnBsK-FexoWfJBZHH9TeZmtFWfCHDLzUcAWOQeE2nYxbQZbJg3MyYQth2kJj3UbIonSFvE4HgOSRwoy2IpzqSE61xl60pDMFN_JbIvww7X0CCB_0hxH9R_6I7YXBd1NjO40gRyuzVEWW4yOfoRN6Gnve3kaDQhMbF7xcEI1rEqhhEGjsgVKA9lE2xau4JGjsZasRf-OzKwX8zxRR_3Agfzz6d9JnbH0wHg2j4cHRp8fslkU1RnJLbIet1fMFf4JOYp08lbbgBwiDZGU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF5CkQo8cLQchgLDIRQenPo-4CnQRmlpqwq1Uh-QLB-7NODYVuxQpb-emd3YqBQQ4slxPKsde2dnZ3ZmvmXsVZDEiS1SW_dwNdUdHph6jCuhHju-n3g8duyYqpH3D7zxsbN74p702Lu2FkbhQ3QbbjQzpL6mCV5lYvMnaGj89XSAxriF_vo1B6_keW196rCjyM43VKDS1APPCFtYIcPa7JpeWIyunlIq5GU78ya7Pi-qeHEW5_lFE1auQaPb7HPLvUo9-TaYN8kgPf8F2PE_X-8Ou7W0TWGohOku6_Fija0PC_TLpwt4DTJbVG7Dr7HV_WVQfv1Kb0dWWkIpoK4oMwPqyTmHuMjkfUFxAWxfFlDOG2SD10RKAX8UXj5JQeLGllU5oYJKoFACNBJzPY9VYVQBaFrDdMFznAoJfspJ_RaGMOPNrGxLRbE_Ba8CyQLQqoVUwf7CFD2NL-oQ4hrOVGwAKpwxkiWCKcgFMdTGJaBWiayyT5nXL19lKtEqLzHW336_f_TmHjsebR99GOvLoyX01LHQYbb8DI29kHP0H400CLMw8FDTJiHqf9RprnB9Kvo1UL6F7QrHthLuZVz4SWJxtEDt-2ylKAv-kIGXGq7ANijappNxK8gyeWxOJmwhTFtorN_KWJQucdfp-I88UojRVoRDHcmh1tiLjrRSYCO_JcIP0z0nePDxcC-i_8gasb0w-G5qbKOV42iplOrIcnzkM3RCT2PPu8eoTmhg44KXc6JxTYI0DAKNPVDy33Vlk7eKC4LGXnYT4m989qV8_5kiGu6O5Y9H_076jK0ebo2ivZ2Dj4_ZDYsSjOR-2AZbaWZz_gQtxCZ5KjXBD5TXYxQ |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5KKoE48Gh5GBU0PITCwSF-29wMahUqUnFopHJy_dilAce2Ypsq_fXM7NoWpYCQuNnxbnbWO7Mz45n5lrGXfhInlkgt3UVtqtvcN_QYNaEe256XuDy2rZiqkedH7mxhH544J905p1QLo_Ahhg9uJBlyvyYBrzKh9vkuum--ib-eTdAgN9Fn36bBzBHbXhx9Cj-rCKWh-65M8jDQUMdrx-yxhX7ue0kjXT-jfMirxuYtdrMtqnhzHuf5ZTtWKqKDO-y0n4LKP_k2aZtkkl78gu74H3O8y253RiqEiqvusS1e7LDdsEAHfbWBVyDTRuX3-B12Y95F53evbX2QJZdQCqgrStGAennBIS4yeV9QgAD7lwWUbYOk8JqaUuQfuZgvU5AAsmVVLqmyEiimAI0EX89jVSFVANrYsNrwHGUiwde5rN9CCGverMu-ZhTHUzgrkGwAzVtIFf4vrNDl-KJOI67hXAUJoELRkSQRXkEuiKA-QAG1ymiVY8oEfzmVlYStvELYeP_d_Pj1fbY42D9-P9O7Myb01DbRcza9DK2-gHN0JKepH2SB7-KWmwSoCHBzc4TjUfXvFBldWI6wLTPhbsaFlyQmR1PUesBGRVnwRwzcdOoI7IM8btgZN_0sk-fnZMISwrCExsY9n0VpB8BO54DkkYKONiNc6kgutcaeD00rhTry20b4YobnhBM-Cz9G9BuZJZYb-N8Nje31vBx1u1MdmbaHdAZ24Grs2fAY9xVa2LjgZUttHIOwDX1fYw-VDAxDWeS2ombQ2ItBKP5G51jy-J9bROHhTF48_qc_3GOjZt3yJ2gNNsnTTuJ_AC_LYtE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+spleen+size+and+splenectomy+on+outcomes+of+allogeneic+hematopoietic+cell+transplantation+for+myelofibrosis%3A+A+retrospective+analysis+by+the+chronic+malignancies+working+party+on+behalf+of+European+society+for+blood+and+marrow+transplantation+%28EBMT%29&rft.jtitle=American+journal+of+hematology&rft.au=Polverelli%2C+Nicola&rft.au=Mauff%2C+Katya&rft.au=Kr%C3%B6ger%2C+Nicolaus&rft.au=Robin%2C+Marie&rft.date=2021-01-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=0361-8609&rft.eissn=1096-8652&rft.volume=96&rft.issue=1&rft.spage=69&rft.epage=79&rft_id=info:doi/10.1002%2Fajh.26020&rft.externalDBID=10.1002%252Fajh.26020&rft.externalDocID=AJH26020 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0361-8609&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0361-8609&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0361-8609&client=summon |